- Home
- CRGX vs FOA Comparison
CRGX vs FOA Comparison
Compare CRGX & FOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- FOA
- Stock Information
- Founded
- CRGX 2021
- FOA 2013
- Country
- CRGX United States
- FOA United States
- Employees
- CRGX N/A
- FOA N/A
- Industry
- CRGX
- FOA Finance Companies
- Sector
- CRGX
- FOA Finance
- Exchange
- CRGX Nasdaq
- FOA Nasdaq
- Market Cap
- CRGX 213.5M
- FOA 198.3M
- IPO Year
- CRGX 2023
- FOA N/A
- Fundamental
- Price
- CRGX $4.02
- FOA $21.42
- Analyst Decision
- CRGX Hold
- FOA Buy
- Analyst Count
- CRGX 7
- FOA 2
- Target Price
- CRGX $4.67
- FOA $26.25
- AVG Volume (30 Days)
- CRGX 763.5K
- FOA 86.0K
- Earning Date
- CRGX 05-16-2025
- FOA 05-06-2025
- Dividend Yield
- CRGX N/A
- FOA N/A
- EPS Growth
- CRGX N/A
- FOA N/A
- EPS
- CRGX N/A
- FOA 3.94
- Revenue
- CRGX N/A
- FOA $429,184,000.00
- Revenue This Year
- CRGX $58.18
- FOA $15.98
- Revenue Next Year
- CRGX N/A
- FOA $9.04
- P/E Ratio
- CRGX N/A
- FOA $5.28
- Revenue Growth
- CRGX N/A
- FOA 155.35
- 52 Week Low
- CRGX $3.00
- FOA $4.10
- 52 Week High
- CRGX $25.45
- FOA $32.40
- Technical
- Relative Strength Index (RSI)
- CRGX 37.02
- FOA 56.29
- Support Level
- CRGX $3.97
- FOA $19.14
- Resistance Level
- CRGX $4.66
- FOA $23.34
- Average True Range (ATR)
- CRGX 0.20
- FOA 1.16
- MACD
- CRGX -0.05
- FOA 0.24
- Stochastic Oscillator
- CRGX 6.25
- FOA 61.16
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.